Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The use of CKRT is essential to treat acute kidney injury (AKI) in hemodynamically unstable critically ill patients. Achieving an effluent dose of 20–25 mL/kg/h, as recommended by KDIGO, provides adequate solute clearance. In this retrospective study, we analyzed the performance of the multiFiltratePRO device, which provides automated monitoring and control of extracorporeal blood circuit, by evaluating the effluent dose and assessed its safety and overall treatment performance.
This retrospective multicenter analysis (NCT06236984) was based on systematically collected data from three sites in Germany using the multiFiltratePRO system. Treatments of adult patients requiring at least one CKRT treatment due to AKI were included. Treatment modalities comprised continuous venovenous hemodialysis (CVVHD), continuous venovenous hemodiafiltration (CVVHDF), and continuous venovenous hemofiltration (CVVH) with systemic heparin (Hep), and CVVHD/CVVHDF with regional citrate (Ci-Ca) anticoagulation. Treatments were documented for up to six days and at the end of treatment. The primary objective was to evaluate achieved effluent dose across CKRT modes and anticoagulation strategies against the KDIGO reference (≥20 mL/kg/h), calculated according to the formula of Neri et al., 2016. Secondary objectives assessed additional performance parameters, including ultrafiltration volume, circuit lifespan, correction of acid-base and electrolyte imbalances, and uremic toxin removal. Safety objectives focused on hemodynamic stability, bleeding, and electrolyte or acid-base disturbances.
Documentation included eighty patients (24 female, 56 male), with 63.8% of patients aged >65 years. Sepsis was the most frequent CKRT indication (50%), and AKI stage 3 the most prevalent stage (55%). Patients were treated with Hep-CVVH (n=2), Hep-CVVHDF (n=4), Ci-Ca-CVVHD (n=54), or Ci-Ca-CVVHDF (n=20). Achieved effluent doses were higher for Ci-Ca modalities (29.5 [SD 6.6] and 40.5 [SD 5.4] mL/kg/h) than for heparin modalities (13.1 [SD 0.9] and 17.2 [SD 4.2] mL/kg/h), with Ci-Ca modalities significantly exceeding the KDIGO-recommended lower limit of 20 mL/kg/h (p <0.0001). Overall, a proportion of 87.5% of patients reached the target effluent dose. Across modalities, prescribed and achieved net ultrafiltration rates were closely aligned. Total solute clearance response was defined as creatinine reduction by at least 0.3 mg/dl or urea/BUN reduction of ≥ 50% from treatment start to end. In Ci-Ca groups, creatinine response was achieved in 75.9% (CVVHD) and 55% (CVVHDF) of patients; urea/BUN response in 66.7% and 50%, respectively. Time to first filter change was 57.7 (SD 3.02) hours for Ci-Ca CVVHD and 63.0 (SD 5.44) hours for Ci-Ca CVVHDF, exceeding the ~47 hours typically expected for Ci-Ca anticoagulation (Zarbock et al., 2020). Across all modalities, most patients achieved acid-base balance by end of treatment.
The multiFiltratePRO device provided effective CKRT with a favorable safety profile in patients with AKI. Ci-Ca modalities consistently achieved or exceeded KDIGO-recommended effluent doses (≥20 mL/kg/h), while conclusions for heparin-treated patients were limited due to small sample size.
